About G1/S-specific cyclin-E2
G1/S-specific cyclin-E2 (CCNE2) is a protein
from Homo sapiens identified by UniProt accession
O96020, 404 residues long.
MolForge cross-references it against 0 known binders and
262 disease associations.
Target properties
| Protein name | G1/S-specific cyclin-E2 |
| UniProt accession | O96020 |
| Gene | CCNE2 |
| Organism | Homo sapiens |
| Length | 404 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (262)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- neurodevelopmental disorder with cerebellar hypoplasia and spasticity · score 0.33
- glioblastoma multiforme · score 0.29
- endometrial cancer · score 0.29
- low grade glioma · score 0.29
- head and neck squamous cell carcinoma · score 0.29
- gastric adenocarcinoma · score 0.29
- esophageal cancer · score 0.29
- breast adenocarcinoma · score 0.29
- squamous cell lung carcinoma · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O96020-F1 | alphafold | PREDICTED | 77.52 | — |
Amino-acid sequence (404 residues)
MSRRSSRLQA KQQPQPSQTE SPQEAQIIQA KKRKTTQDVK KRREEVTKKH QYEIRNCWPP VLSGGISPCI IIETPHKEIG TSDFSRFTNY RFKNLFINPS PLPDLSWGCS KEVWLNMLKK ESRYVHDKHF EVLHSDLEPQ MRSILLDWLL EVCEVYTLHR ETFYLAQDFF DRFMLTQKDI NKNMLQLIGI TSLFIASKLE EIYAPKLQEF AYVTDGACSE EDILRMELII LKALKWELCP VTIISWLNLF LQVDALKDAP KVLLPQYSQE TFIQIAQLLD LCILAIDSLE FQYRILTAAA LCHFTSIEVV KKASGLEWDS ISECVDWMVP FVNVVKSTSP VKLKTFKKIP MEDRHNIQTH TNYLAMLEEV NYINTFRKGG QLSPVCNGGI MTPPKSTEKP PGKH
Explore G1/S-specific cyclin-E2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets